In a pioneering collaboration with AbbVie, Northwestern researchers have discovered a new way to potentially treat cancer by ...
News Medical on MSN2d
Study identifies vitamin E succinate as key to tumor growth controlHigh levels of fat mass and obesity-associated protein (FTO) have been linked to increased tumor growth and resistance to ...
High levels of fat mass and obesity-associated protein (FTO) have been linked to increased tumor growth and resistance to ...
These use E3 ubiquitin ligases to promote the degradation of proteins, rather than inhibiting their function like most traditional small molecules. While a focused class of marketed cancer drugs ...
However, the power of PROTACs lies in the engagement of E3 ligases, and currently, less than two percent of the vast array of E3 ligases in the human genome have been explored in the TPD field. Dr.
Merck Sharp & Dohme LLC patents report the development of proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase (Von Hippel-Lindau disease tumor suppressor [VHL] ligands) ...
Professor Zoran Rankovic’s group is developing PROTACs, Molecular Glue Degraders, and E3 ubiquitin ligase chemical probes to study cancer biology and develop novel cancer drugs. Our group's research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback